Certificate Transfer of Argentine Medical Device Registrations

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Argentine registrations can be transferred (transferencia). ANMAT maintains dedicated transfer fee items and procedures for Classes I, II, III, and IV, covering both domestically manufactured and imported products — all 4 risk classes are covered. The existence of a fee item for every class confirms that transfer is an anticipated, ordinary administrative act, not an exceptional dispensation granted case by case.

Procedurally, the transfer requires cooperation between both parties to the transaction, involves re-notarized authorization, document updates, and fee payment, and takes a practical estimate of about 1–2 months. The real risk lies not in the procedure itself but in the degree of cooperation of the original license holder: if the original holder is a distributor whose commercial interests are bound to the relationship, any change in that relationship leaves the transfer process severely disadvantaged, and imports and sales may both be affected during the interim. Planning the transfer path at the moment of choosing the holder is therefore worth more than any remedy attempted after relations have broken down.

2. Legal basis

RegulationReference numberPublication dateRelevant provisions
Legal basis for fees (including transfer fee items)Disposición ANMAT 2319/2002 (T.O. 2004) and its amendments2002 (2004 consolidated text)Transfer fee item provisions
Operating authorization for manufacturing/importing establishmentsDisposición ANMAT 2319/2002 (T.O. 2004)2002 (2004 consolidated text)License-holder provisions
MERCOSUR technical regulation for medical device registrationGMC/RES 25/21October 13, 2021Part III, Article 6 (manufacturer authorization declaration)
Principal product registration regulationDisposición ANMAT 64/2025Published January 13, 2025 in the Official GazetteRegistration holder provisions

3. Expert insights

Insight 1: The transfer exists as a procedure but is constrained in practice. Existence means companies have a legal path to walk; constraint means whether the path can be walked depends on the original holder’s cooperation. This asymmetry determines the planning consequence: transfer capability should be engineered at the stage of selecting the license holder, not initiated only after the relationship has ruptured. Once a distributor holding the certificate stops cooperating, the manufacturer has a procedure but no practical means to complete it within any predictable timeline.

Insight 2: The re-notarized authorization is the core act of the transfer. Because the registration certificate is bound to the manufacturer’s authorization declaration, a change of the holding entity necessarily triggers the reissuance and notarization of the authorization documents. If the original authorization declaration contains no clause reserving the manufacturer’s right to change the holder, the manufacturer finds itself in a legally passive position — dependent on the very party whose cooperation it can no longer count on. The clause costs little at signing and is nearly impossible to add unilaterally later.

Insight 3: The practical cost of the 1–2 month period is the risk of interrupted imports. Whether products can continue to be imported and sold during the transfer depends on the specific procedural arrangements and ANMAT’s handling of the individual case. For companies with continuous order flow, this 1–2 month window is a real commercial loss in missed shipments and renegotiated delivery dates, which is why buffer inventory is a standard accompaniment of any planned transfer rather than an optional extra.

4. Practical recommendations

  1. Reserve the right to change the holder in the authorization declaration. The manufacturer’s authorization declaration should state that the manufacturer has the right to change the license holder under specified conditions, and require the original holder to cooperate in the transfer.
  2. Stipulate cooperation obligations and time limits in the license-holding agreement. Specify within how many days of notice the original holder must complete document signing and handover, and attach liability for breach so the obligation is enforceable rather than aspirational.
  3. Complete the new holder’s qualification preparation before the transfer. The new holder must already hold the 2319/2002 qualification, the BPF conformity certificate under 3266/2013, and a registered technical director; otherwise the transfer cannot land.
  4. Plan buffer import inventory. Build up stock ahead of the transfer to cover the potential 1–2 month window, so customer deliveries do not depend on the transfer finishing on schedule.

5. Verification checklist

  • □ Confirmed ANMAT maintains transfer procedures and fee items for Classes I–IV
  • □ The authorization declaration reserves the manufacturer’s right to change the holder
  • □ The license-holding agreement stipulates the original holder’s cooperation obligations and time limits
  • □ The new holder’s qualification, BPF certificate, and technical director are in place
  • □ Buffer import inventory arranged against the 1–2 month practical timeline
  • □ Transfer fees included in the budget (transferencia is an independent fee item)

Regulatory information verified as of October 29, 2026.

The checklist above traces the transfer in dependency order, and the order is not cosmetic. The fee items under Disposición 2319/2002 (T.O. 2004) and the holder provisions of Disposición 64/2025 define what must be filed and by whom; the authorization declaration of GMC/RES 25/21 Part III, Article 6 defines whether the manufacturer can lawfully redirect the certificate at all; and the new holder’s qualification package determines whether the transfer, once signed, can actually be accepted. A transfer that begins before the authorization clause and the new holder’s qualifications are confirmed tends to stall in the middle, with the 1–2 month practical timeline stretching indefinitely while shipments wait. Confirming the three dependencies first is what keeps the transfer procedure short and the import window closed for no longer than planned.

In Argentina, GRZAN operates a wholly-owned subsidiary that can serve as the registration holder and importer for foreign manufacturers, directly handling classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the dynamics of regulatory authorities across countries on an ongoing basis. All external content follows the drafting standard of conclusions first, traceable bases, and verifiable figures. For an Argentina or MERCOSUR market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail